SCHEMBL25816910

SCHEMBL25816910

Cc1cnc(N2CCC(C(=O)N3OCC[C@H]3c3cncc(C#N)c3)CC2)nc1C(N)=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 9/20 0.49
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 2/20 0.35
TDP1 Q9NUW8 1/20 0.35
CAMK1D Q8IU85 1/20 0.33
GSK3B P49841 1/20 0.33
DYRK1A Q13627 1/20 0.33
KDM1A O60341 1/20 0.32
CHRNA1 P02708 3/20 0.32
CHRNB4 P30926 3/20 0.32
CHRNA3 P32297 3/20 0.32
CHRNB2 P17787 2/20 0.32
CHRNA4 P43681 2/20 0.32
CHRNG P07510 1/20 0.32
CHRNB1 P11230 1/20 0.32
CHRND Q07001 1/20 0.32
CHRNA2 Q15822 1/20 0.32
JAK2 O60674 1/20 0.32
JAK1 P23458 1/20 0.32
JAK3 P52333 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30338527 1.00 RIPK1 (0.49) RIPK1KDM4EALDH1A1TDP1CAMK1D
SCHEMBL25303686 0.90 RIPK1 (0.53) RIPK1GSK3BDYRK1ATP53
SCHEMBL30338792 0.90 RIPK1 (0.53) RIPK1GSK3BDYRK1ATP53
SCHEMBL30338522 0.87 RIPK1 (0.50) RIPK1JAK2
SCHEMBL25255972 0.87 RIPK1 (0.50) RIPK1JAK2
SCHEMBL30338835 0.86 RIPK1 (0.41) RIPK1
SCHEMBL25253145 0.85 RIPK1 (0.56) RIPK1
SCHEMBL30338649 0.85 RIPK1 (0.56) RIPK1
SCHEMBL30338708 0.85 RIPK1 (0.50) RIPK1KDM4EGSK3BDYRK1ATP53
SCHEMBL25816819 0.85 RIPK1 (0.50) RIPK1KDM4EGSK3BDYRK1ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116547281-A Isoxazolidines as RIPK1 inhibitors and uses thereof 赛诺菲 2023-08-04 CN claimed
CN-116547281-A Isoxazolidines as RIPK1 inhibitors and uses thereof 赛诺菲 2023-08-04 CN disclosed
US-20230219937-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF SANOFI (FR) 2023-07-13 US disclosed
US-20230219937-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF SANOFI (FR) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219937-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF RIPK1, RIPK4, RIPK2 RIPK1 1/4885KDM4E 2270/4885ALDH1A1 2211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.